InMode (INMD) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Q1 2025 revenue was $77.9 million, down 3% year-over-year, reflecting ongoing macroeconomic headwinds and soft consumer demand, especially in the U.S. market, while international sales, particularly in Europe, reached record levels.
Minimally invasive platforms comprised 87% of total revenues, with a broad RF-based portfolio and strong brand recognition, and international sales accounted for 49% of total.
GAAP net income was $18.2 million ($0.26/diluted share), non-GAAP net income was $21.4 million ($0.31/diluted share), and non-GAAP gross margin was 79%.
Management remains committed to maintaining workforce, investing in product development, and launching a new wellness platform later in 2025.
Completed a 6.95 million share repurchase in April 2025, returning $127 million to shareholders; $412 million returned over 12 months, about 27% of share capital.
Financial highlights
Q1 2025 revenue reached $77.9 million; GAAP gross margin was 78% (down from 80%), non-GAAP gross margin was 79%.
GAAP operating expenses were $45.3 million (down 1% year-over-year); non-GAAP operating expenses were $43.1 million (up 2%).
GAAP operating margin was 20% (down from 23%); non-GAAP operating margin was 23% (down from 27%).
Cash, equivalents, and short-term investments totaled $512.9 million as of March 31, 2025; $14 million generated from operating activities in Q1.
Installed base: 12,054 units in the U.S., 27,884 units worldwide.
Outlook and guidance
2025 revenue guidance reiterated at $395–$405 million, with non-GAAP gross margin expected at 78–80% (down from prior 80–82%).
Non-GAAP operating income forecasted at $101–$106 million (prior $130–$135 million); non-GAAP EPS at $1.64–$1.68 (prior $1.95–$1.99).
Guidance assumes Q2 will show seasonal strength; if not, guidance may be revised downward.
Tariffs expected to impact gross margin by 2–3% if current 10% rate holds; further increases could require updated guidance.
Management expects U.S. market headwinds and tariff impacts to persist through year-end.
Latest events from InMode
- Product innovation, high margins, and disciplined capital allocation drive growth amid macro headwinds.INMD
Jefferies Global Healthcare Conference9 Jul 2026 - Strong innovation and global expansion position the firm for recovery despite current headwinds.INMD
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20249 Jul 2026 - Revenue was $130.2M, margins declined, but new platforms gained traction amid headwinds.INMD
Q3 20248 Jul 2026 - Flat revenue outlook, margin pressure, and new products set the stage for future growth.INMD
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q1 2026 revenue reached $82M with 75% gross margin and ongoing share repurchases.INMD
Q1 20266 May 2026 - Growth from new products offsets margin pressure; global expansion and R&D drive future potential.INMD
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Manufacturing and logistics face disruption, but strategic buybacks and global expansion continue.INMD
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - Flat top line expected in 2026, with new products and restructuring to drive future recovery.INMD
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Q4 revenue up 6% to $103.9M, FY sales down 6%, 2026 stable with new launches and strong cash.INMD
Q4 202510 Feb 2026